Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, December 3, 2024, at 4:30 p.m. Eastern time.
A live audio webcast will be accessible through the Investor Relations section of Immunome's website. Following the presentation, a replay will remain available for approximately 30 days.
Immunome (Nasdaq: IMNM), un'azienda biotecnologica specializzata in terapie mirate per il cancro, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per martedì 3 dicembre 2024, alle 16:30 ora orientale.
Un webcast audio dal vivo sarà accessibile attraverso la sezione Relazioni con gli Investitori del sito web di Immunome. Dopo la presentazione, una registrazione resterà disponibile per circa 30 giorni.
Immunome (Nasdaq: IMNM), una empresa biotecnológica especializada en terapias dirigidas contra el cáncer, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La dirección de la empresa participará en un chat informal programado para el martes 3 de diciembre de 2024 a las 4:30 p.m. hora del Este.
Una transmisión en vivo de audio estará disponible a través de la sección de Relaciones con Inversores en el sitio web de Immunome. Después de la presentación, una repetición permanecerá disponible durante aproximadamente 30 días.
Immunome (Nasdaq: IMNM), 타겟 암 치료에 특화된 생명공학 회사가 Piper Sandler 제36회 연례 의료 회의에 참여한다고 발표했습니다. 회사 경영진은 2024년 12월 3일 화요일 오후 4시 30분 동부 표준시에 예정된 대화에 참여할 것입니다.
실시간 오디오 웹 캐스트는 Immunome 웹사이트의 투자자 관계 섹션을 통해 접근할 수 있습니다. 발표 후 약 30일 동안 재생할 수 있습니다.
Immunome (Nasdaq: IMNM), une entreprise biotechnologique spécialisée dans les thérapies ciblées contre le cancer, a annoncé sa participation à la 36ème Conférence Annuelle sur la Santé de Piper Sandler. La direction de l'entreprise participera à une discussion informelle prévue pour mardi 3 décembre 2024 à 16h30, heure de l'Est.
Une diffusion audio en direct sera accessible via la section des Relations avec les Investisseurs du site internet d'Immunome. Après la présentation, un replay sera disponible pendant environ 30 jours.
Immunome (Nasdaq: IMNM), ein biotechnologisches Unternehmen, das sich auf gezielte Krebstherapien spezialisiert hat, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler angekündigt. Das Management des Unternehmens wird an einem Gespräch teilnehmen, das für Dienstag, den 3. Dezember 2024, um 16:30 Uhr Eastern Time angesetzt ist.
Ein Live-Audio-Webcast wird über den Bereich Investor Relations auf der Webseite von Immunome zugänglich sein. Nach der Präsentation wird eine Wiederholung etwa 30 Tage lang verfügbar sein.
- None.
- None.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted by the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expected timing for submission of INDs for its programs and other statements regarding management’s intentions, plans, beliefs, estimates or forecasts for the future based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including risks and uncertainties indicated from time to time described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 13, 2024 and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241127476225/en/
Investor Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
When is Immunome (IMNM) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Immunome's (IMNM) presentation at the Piper Sandler Conference?
How long will Immunome's (IMNM) Piper Sandler Conference presentation replay be available?
What type of presentation will Immunome (IMNM) give at the Piper Sandler Healthcare Conference?
